Kenichi Katsurada
Overview
Explore the profile of Kenichi Katsurada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haze T, Katsurada K, Sakata S, Kuwabara M, Nishida N, Azegami T, et al.
Hypertens Res
. 2025 Feb;
PMID: 39948181
We conducted a systematic review and meta-analysis to evaluate the effects of intensive versus standard antihypertensive therapy on cardiovascular outcomes in adult patients with hypertension. The primary endpoints were composite...
2.
Katsurada K, Kario K
Hypertens Res
. 2024 Aug;
47(10):2700-2710.
PMID: 39210082
Renal denervation (RDN) is a neuromodulation therapy performed in patients with hypertension using an intraarterial catheter. Recent randomized sham-controlled trials have shown that RDN has significant antihypertensive effects that last...
3.
Katsurada K, Kario K
Hypertens Res
. 2024 Aug;
47(10):2693-2699.
PMID: 39112539
Renal denervation (RDN) is a neuromodulation therapy performed using an intraarterial catheter in patients with hypertension. Recent randomized sham-operated controlled trials have shown that RDN has significant antihypertensive effects in...
4.
Ogoyama Y, Abe M, Okamura K, Tada K, Katsurada K, Shibata S, et al.
Hypertens Res
. 2024 Jun;
47(10):2975.
PMID: 38918532
No abstract available.
5.
Ogoyama Y, Abe M, Okamura K, Tada K, Katsurada K, Shibata S, et al.
Hypertens Res
. 2024 Jun;
47(10):2745-2759.
PMID: 38831091
The efficacy of renal denervation (RDN) has been controversial, but recent randomized sham-controlled trials demonstrated significant blood pressure reductions after RDN in patients with hypertension. We conducted a systematic review...
6.
Katsurada K, Patel K
Hypertens Res
. 2024 Apr;
47(7):1978-1980.
PMID: 38632458
No abstract available.
7.
8.
Nandi S, Katsurada K, Moulton M, Zheng H, Patel K
Front Physiol
. 2024 Jan;
14:1277065.
PMID: 38169715
Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome characterized by diastolic dysfunction, concentric cardiac left ventricular (LV) hypertrophy, and myocardial fibrosis with preserved systolic function. However,...
9.
Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K, et al.
Hypertens Res
. 2023 Sep;
47(1):6-32.
PMID: 37710033
Total 276 manuscripts were published in Hypertension Research in 2022. Here our editorial members picked up the excellent papers, summarized the current topics from the published papers and discussed future...
10.
Katsurada K, Kario K
Hypertens Res
. 2023 Mar;
46(6):1462-1470.
PMID: 36991064
Inappropriate sympathetic activation is closely associated with the development and progression of hypertension. Renal denervation (RDN) is a neuromodulation therapy performed using an intraarterial catheter in patients with hypertension. Recent...